Effect of Nigella sativa oil in patients with polycystic ovary syndrome
- Conditions
- Polycystic ovary syndrome.Polycystic ovarian syndromeE28.2
- Registration Number
- IRCT20230125057222N1
- Lead Sponsor
- Ardabil University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 60
Oligomenorrhea or lack of ovulation
Polycystic ovaries based on ultrasound
Androgenic hormone changes in laboratory or clinical form (the presence of hirsutism)
Type 2 diabetes -
thyroid disease -
adrenal hyperplasia
autoimmune diseases -
- hyperprolactinemia
People with structured physical activity or scheduled exercise
If three months before entering the study, they use a special diet or special drugs that may affect the results, they will be excluded from the study, such as anti-obesity drugs, ovulation stimulants, antidepressants, insulin sensitivity, oral contraceptives, aspirin, and Anti-prostaglandin drugs
If there are signs of pregnancy, they will be excluded from the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Interleukin 6,. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.;TNF-alpha. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.;Lipid profile. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.;Insulin. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.;Fasting blood sugar. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.
- Secondary Outcome Measures
Name Time Method Insulin resistance index (QUICKI), insulin sensitivity index (HOMA-IR). Timepoint: Before and 12 weeks after the intervention. Method of measurement: Calculation of indices.